Lymphoma Tumor Board News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jakub Svoboda, MD, discusses outcomes with armored huCART19-IL18 in patients with previously treated relapsed/refractory lymphomas that have progressed.

Jakub svobodaHospital of the university pennsylvaniaData safety monitoring committeeAbramson cancer centerLymphoma tumor boardCase conference